Scholarlink

Background and objectives <p>GLP-1–based medications have rapidly reshaped the landscape of obesity treatment. Semaglutide was approved for obesity treatment in 2021 in the US and 2022 in Europe, sparking global interest, and the GLP-1/GIP dual-agonist tirzepatide has demonstrated even greater efficacy. However, survey-based data on who uses or considers these medications—particularly across socioeconomic groups, BMI categories, and weight management experiences—remain limited.</p> Subjects/methods <p>A nationally representative online survey of Finnish adults (<i>n</i> = 1729, of which 1693 were included) was conducted in June 2025 via a market research company using quota sampling. Use and awareness of GLP-1 medications for obesity were measured with a single item listing widely known brands—Ozempic, Wegovy, Zepbound, and Mounjaro—to aid recognition. In regression analyses, current, past, and potential users (<i>n</i> = 322) were combined.</p> Results <p>In total, 3.5% reported current and 2.0% past use, and 13.5% expressed interest in future use. Notably, ~40% of individuals with obesity reported no interest. Bivariate analysis showed that current use was more common among women, those aged 50–69, those with household income exceeding €70,000, individuals with higher BMI, frequent weight loss attempts, experiences of weight-based discrimination, and self-blame. Multivariable analysis showed that current, past, and potential use had strongest associations with BMI ≥30.0 kg/m², repeated or persistent weight loss attempts, experiences of discriminatory treatment due to weight, self-blaming thoughts and hopeful perceptions of GLP-1 medications. Concern about serious health risks was associated with lower likelihood of use or interest.</p> Conclusions <p>GLP-1–based medications are gaining recognition, but uptake remains heterogeneous and many individuals with obesity remain uninterested. Concerns about potential health risks persist. Attitudes toward these medications are shaped not only by weight status but also by prior weight management experiences and perceptions. Clinical communication should be sensitive to these factors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

GLP-1 medications: use and interest in a representative survey of Finns

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月7日

查看全文
  • Piia Tuuli Jallinoja,
  • Kirsi H. Pietiläinen,
  • Virginia W. Chang

摘要

Background and objectives

GLP-1–based medications have rapidly reshaped the landscape of obesity treatment. Semaglutide was approved for obesity treatment in 2021 in the US and 2022 in Europe, sparking global interest, and the GLP-1/GIP dual-agonist tirzepatide has demonstrated even greater efficacy. However, survey-based data on who uses or considers these medications—particularly across socioeconomic groups, BMI categories, and weight management experiences—remain limited.

Subjects/methods

A nationally representative online survey of Finnish adults (n = 1729, of which 1693 were included) was conducted in June 2025 via a market research company using quota sampling. Use and awareness of GLP-1 medications for obesity were measured with a single item listing widely known brands—Ozempic, Wegovy, Zepbound, and Mounjaro—to aid recognition. In regression analyses, current, past, and potential users (n = 322) were combined.

Results

In total, 3.5% reported current and 2.0% past use, and 13.5% expressed interest in future use. Notably, ~40% of individuals with obesity reported no interest. Bivariate analysis showed that current use was more common among women, those aged 50–69, those with household income exceeding €70,000, individuals with higher BMI, frequent weight loss attempts, experiences of weight-based discrimination, and self-blame. Multivariable analysis showed that current, past, and potential use had strongest associations with BMI ≥30.0 kg/m², repeated or persistent weight loss attempts, experiences of discriminatory treatment due to weight, self-blaming thoughts and hopeful perceptions of GLP-1 medications. Concern about serious health risks was associated with lower likelihood of use or interest.

Conclusions

GLP-1–based medications are gaining recognition, but uptake remains heterogeneous and many individuals with obesity remain uninterested. Concerns about potential health risks persist. Attitudes toward these medications are shaped not only by weight status but also by prior weight management experiences and perceptions. Clinical communication should be sensitive to these factors.